In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018

A look at the financing, M&A and alliance activity in January-March 2018

Executive Summary

Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.

You may also be interested in...



Varian Stands Firm Against Rival Bid For SirTex; What Next If It All Falls Down?

Varian Medical Systems' proposed $1.3bn deal to acquire SirTex Medical is officially in jeopardy after China's CDH Investments formalized its rival bid to snatch away the Australian interventional oncology firm. Should the deal fall through, what would Varian's next steps be?

'Watch This Space' Roche Execs Say, Outlining RWE Rationale For Flatiron Buy

Buying Flatiron Health offers research-quality electronic medical records data which will help gain access to patients and help in the drug development and reimbursement process, Roche exes say.

Boston Scientific Scores March M&A Double Whammy With NxThera

In its second acquisition deal this month, Boston Scientific has agreed to pay up to $406m for NxThera, maker of the Rezῡm system for treating benign prostatic hyperplasia.

Related Content

Topics

Related Deals

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel